SANTA BARBARA, Calif., Feb. 07, 2017 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, today announced the appointment of aesthetics industry veteran executive Dr. Philippe A. Schaison to the Company’s board of directors, effective February 6, 2017.
Jeffrey M. Nugent, Chairman and Chief Executive Officer of Sientra, said, “As one of the premier leaders of the global aesthetics industry, I have known Philippe for some time and I am confident that he will bring a unique perspective and will add to our board’s deep focus on this category. We believe his experience and insight in building, acquiring, growing, and leading world class aesthetic products and brands will be instrumental to the growth of our business. His appointment comes at a critical juncture for Sientra, as we continue to make progress toward comprehensive manufacturing supply and on our longer-term objective of becoming a world class, diversified aesthetics organization.”
Dr. Schaison has extensive experience leading global aesthetic organizations. In November, 2016, Dr. Schaison joined Syneron Medical Ltd., (NASDAQ:ELOS), a leading global aesthetic device company, and currently serves as CEO of Syneron Candela North America and Global Executive Vice President Strategy and Business Development. Previously, Dr. Schaison served as President of Allergan’s U.S. aesthetic and dermatology business. In that position, he led the Facial Aesthetic, Plastic and MedDerm/Skin Medical business unit, an organization of over 2,000 professionals focused on the company’s Botox® and fillers franchises.
Prior to joining Allergan, Dr. Schaison served as President, World Wide Travel Retail & Regional President, LATAM and MEA, at Clarins in New York. Earlier, Dr. Schaison served as CEO for Aesthetic Factors, a manufacturer of point-of-care systems for regenerative medicines and as Vice President of Global Skin Care for Johnson & Johnson, with P&L responsibility for Aveeno, Clean & Clear, Lubriderm, and Ambi, and in executive positions at L'Oréal. Dr. Schaison sits on the Board of the Galien Foundation and SENTÉ, Inc., a privately held specialty aesthetics company. He earned his MBA (Marketing) from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy (Industrial) from the University of Paris.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products including bioCorneum®, the professional choice in scar management.
Forward-looking statements
Any forward-looking statements are subject to risks and uncertainties such as those described in Sientra’s most recently filed Quarterly Report on Form 10-Q and and its Annual Report on Form 10-K for the year ended December 31, 2015 which Sientra filed with the Securities and Exchange Commission on March 10, 2016. Actual results may differ materially from anticipated results.
Investor Contacts: Patrick F. Williams Sientra, Chief Financial Officer (619) 675-1047 [email protected] Nick Laudico / Brian Johnston The Ruth Group (646) 536-7030 / (646) 536-7028 [email protected]


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



